ICCC Stock Overview
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
ImmuCell Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.42 |
| 52 Week High | US$10.96 |
| 52 Week Low | US$5.98 |
| Beta | 0.59 |
| 1 Month Change | 21.70% |
| 3 Month Change | -5.73% |
| 1 Year Change | -7.20% |
| 3 Year Change | 49.07% |
| 5 Year Change | 5.30% |
| Change since IPO | 642.39% |
Recent News & Updates
ImmuCell GAAP EPS of -$0.09, revenue of $3.86M
Aug 11ImmuCell announces preliminary 2Q sales of $3.9M
Jul 07Recent updates
Health Check: How Prudently Does ImmuCell (NASDAQ:ICCC) Use Debt?
Sep 15
Why We Think Shareholders May Be Considering Bumping Up ImmuCell Corporation's (NASDAQ:ICCC) CEO Compensation
Jun 10Is ImmuCell (NASDAQ:ICCC) Using Too Much Debt?
Mar 15Does ImmuCell's (NASDAQ:ICCC) Share Price Gain of 38% Match Its Business Performance?
Jan 22Shareholder Returns
| ICCC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.3% | -0.2% | 1.7% |
| 1Y | -7.2% | 3.9% | -12.5% |
Return vs Industry: ICCC underperformed the US Biotechs industry which returned 1.2% over the past year.
Return vs Market: ICCC exceeded the US Market which returned -13.6% over the past year.
Price Volatility
| ICCC volatility | |
|---|---|
| ICCC Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 12.3% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ICCC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: ICCC's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 68 | Michael Brigham | https://immucell.com |
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets.
ImmuCell Corporation Fundamentals Summary
| ICCC fundamental statistics | |
|---|---|
| Market Cap | US$57.51m |
| Earnings (TTM) | -US$751.80k |
| Revenue (TTM) | US$20.10m |
2.9x
P/S Ratio-76.5x
P/E RatioIs ICCC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ICCC income statement (TTM) | |
|---|---|
| Revenue | US$20.10m |
| Cost of Revenue | US$10.88m |
| Gross Profit | US$9.22m |
| Other Expenses | US$9.97m |
| Earnings | -US$751.80k |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Feb 22, 2023
| Earnings per share (EPS) | -0.097 |
| Gross Margin | 45.86% |
| Net Profit Margin | -3.74% |
| Debt/Equity Ratio | 32.8% |
How did ICCC perform over the long term?
See historical performance and comparison